Drug
Rpl554 Plus Tiotropium
Rpl554 Plus Tiotropium: highest development phase Phase 2, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| 1.5 mg RPL554 plus tiotropium NCT03028142 | Phase 2 | Chronic Obstructive Pulmonary Disease Moderate |
Latest
No recent events.
Follow Rpl554 Plus Tiotropium on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.